Psychobiotics Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 143.01 Million
CAGR (2026-2031)	3.29%
Fastest Growing Segment	Liquid/Fluid
Largest Market	North America
Market Size (2031)	USD 173.67 Million

Market Overview

The Global Psychobiotics Market is projected to grow from USD 143.01 Million in 2025 to USD 173.67 Million by 2031 at a 3.29% CAGR. Psychobiotics are defined as live organisms that, when administered in adequate amounts, confer mental health benefits to the host by modulating the gut-brain axis. The global psychobiotics market is primarily driven by increasing consumer awareness regarding the profound link between gut health and psychological well-being, alongside a rising prevalence of mental health concerns such as stress and anxiety. Furthermore, growing scientific evidence supporting the efficacy of these targeted microbial interventions fosters market expansion, as consumers seek natural, non-pharmacological solutions for mood and cognitive support.

However, the market faces a notable challenge in the form of regulatory complexities and the need for standardized clinical validation to substantiate specific health claims, which can impede product development and market acceptance. While specific 2025 psychobiotics market data from industrial associations remains limited, the broader probiotic supplements market, encompassing psychobiotics, demonstrates significant activity. According to the International Probiotics Association, in 2023, the global probiotic supplements market size was USD 9.0 billion.

Key Market Drivers

The global psychobiotics market is significantly influenced by the increasing global burden of mental health disorders. The pervasive rise in conditions such as stress, anxiety, and depression creates an urgent demand for novel and effective interventions. As consumers and healthcare systems increasingly seek proactive and complementary approaches to mental well-being, psychobiotics emerge as a promising category. This demand is underscored by the sheer scale of the challenge; according to the Institute for Health Metrics and Evaluation, 15% of the world's population experienced mental disorders in 2023. This widespread prevalence drives both research investment and consumer adoption of solutions that aim to support mental health naturally.

Further propelling the market are advancements in gut-brain axis research and validation. Ongoing scientific discovery continues to elucidate the intricate bidirectional communication pathways between the gut microbiome and the central nervous system, providing a robust scientific foundation for psychobiotics. This deepening understanding fosters innovation in product development and strengthens the credibility of psychobiotic health claims. For instance, according to Grants.gov, in July 2025, a Notice of Funding Opportunity from the National Institute of Environmental Health Sciences (NIEHS) for research on the gut microbiome-brain axis indicated a potential award of $4,000,000. Such dedicated funding fuels further exploration into mechanisms and efficacy, bolstering the market's growth. The overarching economic impact of mental health issues also underscores the market's relevance; according to UN News, in 2025, citing the World Health Organization, depression and anxiety alone cost the global economy an estimated US$1 trillion each year.

Download Free Sample Report

Key Market Challenges

A significant challenging factor impacting the Global Psychobiotics Market is the combination of regulatory complexities and the stringent need for standardized clinical validation to substantiate specific health claims. These regulatory hurdles impede market entry and product development. The fragmented regulatory landscape across various jurisdictions leads to inconsistent classification, labeling, and health claim requirements for psychobiotic products. This lack of harmonization necessitates that manufacturers adapt their products to differing national guidelines, which subsequently increases development costs and extends timelines for market introduction.

Furthermore, the rigorous requirement for robust clinical validation to support explicit mental health benefits directly restrains market expansion. Conducting the necessary gold-standard human clinical trials for novel psychobiotic strains, especially those targeting complex psychological outcomes, represents a considerable financial and operational burden for companies. Without clear, scientifically substantiated claims that are accepted by regulatory authorities, consumer and healthcare professional confidence remains cautious, thereby hindering broader adoption. According to an August 2025 report prepared for International Probiotic Association Europe, out of 355 probiotic-related health claims assessed by EFSA, only one received approval. This illustrates the difficulty in gaining regulatory acceptance for health claims, directly impacting innovation and market acceptance within the psychobiotics sector.

Key Market Trends

A primary trend in the Global Psychobiotics Market is the accelerating shift towards personalized psychobiotic formulations. This involves tailoring microbial interventions to individual gut microbiomes, genetic predispositions, and specific mental health needs. Such precision aims to enhance treatment efficacy for conditions like stress and anxiety, moving beyond generic solutions. Improved diagnostics are crucial, fostering consumer trust and enabling premium offerings by deeply understanding individual gut-brain axis interactions. For instance, the Biocodex Microbiota Foundation, in April 2026, announced a $50,000 USD grant for research into "Harnessing the Gut Microbiome: Impacts on Health, Disease, Diagnosis and Therapeutics", highlighting ongoing scientific investment.

The convergence of psychobiotics with digital health and artificial intelligence platforms represents another significant market trend. This integration offers innovative avenues for product development and consumer engagement. AI and machine learning are increasingly vital for advanced microbiome analysis, identifying specific psychobiotic strains for mental benefits and optimizing formulations. Digital platforms facilitate personalized recommendations, remote gut health monitoring, and improved adherence, enriching user experience and expanding market reach. These technological synergies are creating data-driven ecosystems, poised to redefine psychobiotic research, prescription, and consumption. According to Google.org, in January 2026, it launched a $20 million AI for Science Fund supporting organizations focused on cutting-edge AI for science research, including microbiome foundation models.

Segmental Insights

The Liquid/Fluid segment is emerging as the fastest-growing category within the Global Psychobiotics Market due to evolving consumer preferences and distinct product advantages. This rapid expansion is primarily driven by the increasing demand for convenient, portable, and ready-to-consume wellness solutions that seamlessly integrate into daily routines. Liquid psychobiotics, often delivered as functional beverages or shots, appeal to consumers seeking perceived quicker absorption and faster noticeable effects for mental well-being benefits such as mood enhancement and stress reduction. Furthermore, this format aligns with the broader "food-as-medicine" trend, enabling wider market penetration beyond traditional supplement users.

Regional Insights

North America dominates the global psychobiotics market, primarily driven by substantial investments in microbiome research and development initiatives. The region exhibits high consumer awareness regarding the intricate gut-brain axis and its impact on mental well-being, fostering robust demand for related health solutions. A mature dietary supplement market, coupled with significant healthcare expenditure, further contributes to this leadership. Additionally, the presence of numerous key industry players and a supportive regulatory framework for dietary supplements, as overseen by bodies like the Food and Drug Administration, facilitates product innovation and market penetration, solidifying North America’s prominent position.

Recent Developments

In December 2025, PureWell Sciences introduced its new Psychobiotics product, targeting women's wellness by focusing on the gut-brain connection. This next-generation supplement was formulated to restore balance in the gut microbiome and thereby enhance mood, focus, and overall mental well-being. Unlike conventional probiotics, PureWell Psychobiotics combined prebiotics, probiotics, and postbiotics, including specialized strains like Lactobacillus helveticus and Bifidobacterium longum, to address stress, anxiety, and mental clarity through neurotransmitter production and inflammation reduction.
In September 2025, AB-Biotics introduced Mindbiome Plus, a new psychobiotic blend designed to enhance mental functions such as concentration and memory, directly contributing to the global psychobiotics market. This innovative formulation contained Levilactobacillus brevis KABP 052 and Lactiplantibacillus plantarum KABP 023, strains specifically chosen for their capacity to promote the production of various neuroactive substances, including GABA. The company was actively exploring the potential of Mindbiome Plus to support neurodevelopmental conditions like autism spectrum disorder and attention deficit hyperactivity disorder, which are frequently linked to GABA imbalances.
In September 2025, Novonesis and Novo Nordisk announced a collaboration to further investigate the connection between microbiome balance and metabolic health. This partnership aimed to explore how pre- and probiotic synbiotic food supplements could influence factors such as cholesterol and blood glucose levels, demonstrating an expanding scope within the global psychobiotics market. This research into the gut-brain-metabolic axis represents a significant step towards understanding how gut microbes can impact overall well-being beyond traditional digestive health.
In September 2025, ADM launched a new postbiotic solution, Lactobacillus gasseri CP2305, expanding its health and wellness portfolio within the global psychobiotics sector. This new offering was supported by eight clinical trials that demonstrated its capacity to assist various aspects of wellness through the gut-brain axis. Specifically, three of these trials indicated that supplementation with L. gasseri CP2305 could support emotional well-being, contribute to reduced stress, and be associated with improved sleep efficiency and overall sleep quality.

Key Market Players

InnovixLabs
Bened Biomedical Co., Ltd
Nutrimmun GmbH
Kerry Group Plc.
Sabinsa Corporation
Lallemand Health Solutions Inc.
DuPont de Nemours, Inc.
Uplift Food Pty Ltd.
Nature's Bounty Co. Ltd.
BioGaia Group

By Psychotropic Agent	By Form	By Application	By Distribution Channel	By Region
Streptococcus Bifidobacterium Lactobacillus Clostridium Others	Powder Liquid/Fluid Tablets Others	Stress Management Mood Health & Mood Upliftment Depression Anxiety Sleep Problems Others	Supermarkets and Hypermarkets Specialty Stores Online Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Psychobiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent:

Streptococcus
Bifidobacterium
Lactobacillus
Clostridium
Others

Psychobiotics Market, By Form:

Powder
Liquid/Fluid
Tablets
Others

Psychobiotics Market, By Application:

Stress Management
Mood Health & Mood Upliftment
Depression
Anxiety
Sleep Problems
Others

Psychobiotics Market, By Distribution Channel:

Supermarkets and Hypermarkets
Specialty Stores
Online
Others

Psychobiotics Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychobiotics Market.

Available Customizations:

Global Psychobiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Psychobiotics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychobiotics Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

5.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

5.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

5.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

5.2.5. By Region

5.2.6. By Company (2025)

5.3. Market Map

6. North America Psychobiotics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Psychotropic Agent

6.2.2. By Form

6.2.3. By Application

6.2.4. By Distribution Channel

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Psychobiotics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Psychotropic Agent

6.3.1.2.2. By Form

6.3.1.2.3. By Application

6.3.1.2.4. By Distribution Channel

6.3.2. Canada Psychobiotics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Psychotropic Agent

6.3.2.2.2. By Form

6.3.2.2.3. By Application

6.3.2.2.4. By Distribution Channel

6.3.3. Mexico Psychobiotics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Psychotropic Agent

6.3.3.2.2. By Form

6.3.3.2.3. By Application

6.3.3.2.4. By Distribution Channel

7. Europe Psychobiotics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Psychotropic Agent

7.2.2. By Form

7.2.3. By Application

7.2.4. By Distribution Channel

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Psychobiotics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Psychotropic Agent

7.3.1.2.2. By Form

7.3.1.2.3. By Application

7.3.1.2.4. By Distribution Channel

7.3.2. France Psychobiotics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Psychotropic Agent

7.3.2.2.2. By Form

7.3.2.2.3. By Application

7.3.2.2.4. By Distribution Channel

7.3.3. United Kingdom Psychobiotics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Psychotropic Agent

7.3.3.2.2. By Form

7.3.3.2.3. By Application

7.3.3.2.4. By Distribution Channel

7.3.4. Italy Psychobiotics Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Psychotropic Agent

7.3.4.2.2. By Form

7.3.4.2.3. By Application

7.3.4.2.4. By Distribution Channel

7.3.5. Spain Psychobiotics Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Psychotropic Agent

7.3.5.2.2. By Form

7.3.5.2.3. By Application

7.3.5.2.4. By Distribution Channel

8. Asia Pacific Psychobiotics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Psychotropic Agent

8.2.2. By Form

8.2.3. By Application

8.2.4. By Distribution Channel

8.2.5. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Psychobiotics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Psychotropic Agent

8.3.1.2.2. By Form

8.3.1.2.3. By Application

8.3.1.2.4. By Distribution Channel

8.3.2. India Psychobiotics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Psychotropic Agent

8.3.2.2.2. By Form

8.3.2.2.3. By Application

8.3.2.2.4. By Distribution Channel

8.3.3. Japan Psychobiotics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Psychotropic Agent

8.3.3.2.2. By Form

8.3.3.2.3. By Application

8.3.3.2.4. By Distribution Channel

8.3.4. South Korea Psychobiotics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Psychotropic Agent

8.3.4.2.2. By Form

8.3.4.2.3. By Application

8.3.4.2.4. By Distribution Channel

8.3.5. Australia Psychobiotics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Psychotropic Agent

8.3.5.2.2. By Form

8.3.5.2.3. By Application

8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Psychobiotics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Psychotropic Agent

9.2.2. By Form

9.2.3. By Application

9.2.4. By Distribution Channel

9.2.5. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Psychobiotics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Psychotropic Agent

9.3.1.2.2. By Form

9.3.1.2.3. By Application

9.3.1.2.4. By Distribution Channel

9.3.2. UAE Psychobiotics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Psychotropic Agent

9.3.2.2.2. By Form

9.3.2.2.3. By Application

9.3.2.2.4. By Distribution Channel

9.3.3. South Africa Psychobiotics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Psychotropic Agent

9.3.3.2.2. By Form

9.3.3.2.3. By Application

9.3.3.2.4. By Distribution Channel

10. South America Psychobiotics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Psychotropic Agent

10.2.2. By Form

10.2.3. By Application

10.2.4. By Distribution Channel

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Psychobiotics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Psychotropic Agent

10.3.1.2.2. By Form

10.3.1.2.3. By Application

10.3.1.2.4. By Distribution Channel

10.3.2. Colombia Psychobiotics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Psychotropic Agent

10.3.2.2.2. By Form

10.3.2.2.3. By Application

10.3.2.2.4. By Distribution Channel

10.3.3. Argentina Psychobiotics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Psychotropic Agent

10.3.3.2.2. By Form

10.3.3.2.3. By Application

10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Psychobiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. InnovixLabs

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Bened Biomedical Co., Ltd

15.3. Nutrimmun GmbH

15.4. Kerry Group Plc.

15.5. Sabinsa Corporation

15.6. Lallemand Health Solutions Inc.

15.7. DuPont de Nemours, Inc.

15.8. Uplift Food Pty Ltd.

15.9. Nature's Bounty Co. Ltd.

15.10. BioGaia Group

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Psychobiotics Market in 2025?

Which is the dominating region in the Global Psychobiotics Market?

Which is the fastest growing segment in the Global Psychobiotics Market?

What is the expected growth rate of the Global Psychobiotics Market?